Literature DB >> 31672802

The dangers of compounded bioidentical hormone replacement therapy.

Louise Newson1, Janice Rymer2.   

Abstract

Mesh：

Substances：

Year:  2019        PMID： 31672802      PMCID： PMC6808563          DOI： 10.3399/bjgp19X706169

Source DB:  PubMed          Journal:  Br J Gen Pract        ISSN： 0960-1643            Impact factor:   5.386


× No keyword cloud information.
  13 in total

1.  Progesterone skin cream and measurements of absorption.

Authors:  R Don Gambrell
Journal:  Menopause       Date:  2003 Jan-Feb       Impact factor: 2.953

2.  2016 IMS Recommendations on women's midlife health and menopause hormone therapy.

Authors:  R J Baber; N Panay; A Fenton
Journal:  Climacteric       Date:  2016-02-12       Impact factor: 3.005

3.  What are the concerns about custom-compounded "bioidentical" hormone therapy?

Authors:  JoAnn V Pinkerton
Journal:  Menopause       Date:  2014-12       Impact factor: 2.953

Review 4.  Custom-compounded bioidentical hormone therapy: why so popular despite potential harm? The case against routine use.

Authors:  M L'Hermite
Journal:  Climacteric       Date:  2017-02-09       Impact factor: 3.005

5.  Effectiveness of transdermal oestradiol and natural micronised progesterone for menopausal symptoms.

Authors:  Louise R Newson; Amir Lass
Journal:  Br J Gen Pract       Date:  2018-10       Impact factor: 5.386

6.  The impact of micronized progesterone on breast cancer risk: a systematic review.

Authors:  P Stute; L Wildt; J Neulen
Journal:  Climacteric       Date:  2018-01-31       Impact factor: 3.005

7.  The need to do better - Are we still letting our patients down and at what cost?

Authors:  Grant Philip Cumming; Heather Currie; Edward Morris; Rik Moncur; Amanda J Lee
Journal:  Post Reprod Health       Date:  2015-05-11

8.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.

Authors:  Jacques E Rossouw; Garnet L Anderson; Ross L Prentice; Andrea Z LaCroix; Charles Kooperberg; Marcia L Stefanick; Rebecca D Jackson; Shirley A A Beresford; Barbara V Howard; Karen C Johnson; Jane Morley Kotchen; Judith Ockene
Journal:  JAMA       Date:  2002-07-17       Impact factor: 56.272

9.  Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence.

Authors: 
Journal:  Lancet       Date:  2019-08-29       Impact factor: 79.321

10.  Why women choose compounded bioidentical hormone therapy: lessons from a qualitative study of menopausal decision-making.

Authors:  Jennifer Jo Thompson; Cheryl Ritenbaugh; Mark Nichter
Journal:  BMC Womens Health       Date:  2017-10-02       Impact factor: 2.809
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.